Efficacy and Safety of Peginterferon in ET and PV.
Status:
RECRUITING
Trial end date:
2027-11-20
Target enrollment:
Participant gender:
Summary
This is a single-arm, single-center study aims to recruit 40 participants with Essential Thrombocythemia (ET) and Polycythemia Vera (PV). Eligible participants will receive a subcutaneous injection of Peginterferon -2b 180 mcg once a week and follow-upand efficacy and safety will be evaluated.